WARREN BUFFETT INCREASES STAKE IN TEVA TO 4.3%
NEWS - 2 DAYS AGO
Billionaire investor Warren Buffett increased his stake in Teva Pharmaceutical Industries to 4.3% during the second quarter of 2018, according to the quarterly financial statement from his investments firm Berkshire Hathaway. ... Altogether its stake is worth $957 million, according to Teva's closing price on Tuesday.
TEVA HAS A STRONG PIPELINE OF NEW DRUGS COMING TO MARKET
Billionaire investor Warren Buffett increased his stake in Teva Pharmaceutical Industries to 4.3% during the second quarter of 2018, according to the quarterly financial statement from his investments firm Berkshire Hathaway. ... Altogether its stake is worth $957 million, according to Teva's closing price on Tuesday.
TEVA HAS A STRONG PIPELINE OF NEW DRUGS COMING TO MARKET
Trade active:
GREAT ARTICLE..!!
I DO NOT THINK TEVA HAS MOVED UP YET. IF YOU WAIT UNTIL THEY ANNOUNCE THE DISTRIBUTION AGREEMENT, YOU MIGHT MISS THE RUN UP!!
arstechnica.com...e-price-is-tbd/?amp=1
I DO NOT THINK TEVA HAS MOVED UP YET. IF YOU WAIT UNTIL THEY ANNOUNCE THE DISTRIBUTION AGREEMENT, YOU MIGHT MISS THE RUN UP!!
arstechnica.com...e-price-is-tbd/?amp=1
Trade active:
BTW..I AM NOT YELLING. I LIKE TYPING IN CAPITALS. IT'S EASIER TO READ.
SO, FYI TO ALL INVESTORS
THE FDA APPROVAL OF A GENERIC EPIPEN IS HUGE, BIGGER THAN A DIABETIC PUMP.
LOOK AT THE PRICE OF TANDEM (TNDM)...TEVA IS TEN TIMES THE COMPANY AND WORTH OVER TRIPLE THE PRICE OF TANDEM.
WALL STREET HAS NO CLUE HOW BIG THE FDA APPROVAL FOR THE "ONLY" GENERIC EPIPEN IS.
THERE ARE AT LEASE 4 TO 6 COMPANIES AND MORE IN THE WORKS PUSHING DIABETIC PUMPS.
THERE ARE ONLY TWO (2) COMPANIES WITH EPIPENS
MYLAN, WHICH EVERYONE HATES BECAUSE THE COMPANY SCREWED PEOPLE AND JACKED THE PRICE UP TO $600 / $300...
AND THEN YOU HAVE TEVA WHO JUST GOT THE ONLY FDA APPROVAL FOR A GENERIC EPIPEN...TEVA SETTLED WITH MYLAN YEARS AGO AND MYLAN GAVE TEVA PERMISSION TO SELL THE EPIPEN.
THERE IS NOTHING ELSE!!
TEVA SHOULD OWN THE MARKET INTO THE FUTURE!
SO, FYI TO ALL INVESTORS
THE FDA APPROVAL OF A GENERIC EPIPEN IS HUGE, BIGGER THAN A DIABETIC PUMP.
LOOK AT THE PRICE OF TANDEM (TNDM)...TEVA IS TEN TIMES THE COMPANY AND WORTH OVER TRIPLE THE PRICE OF TANDEM.
WALL STREET HAS NO CLUE HOW BIG THE FDA APPROVAL FOR THE "ONLY" GENERIC EPIPEN IS.
THERE ARE AT LEASE 4 TO 6 COMPANIES AND MORE IN THE WORKS PUSHING DIABETIC PUMPS.
THERE ARE ONLY TWO (2) COMPANIES WITH EPIPENS
MYLAN, WHICH EVERYONE HATES BECAUSE THE COMPANY SCREWED PEOPLE AND JACKED THE PRICE UP TO $600 / $300...
AND THEN YOU HAVE TEVA WHO JUST GOT THE ONLY FDA APPROVAL FOR A GENERIC EPIPEN...TEVA SETTLED WITH MYLAN YEARS AGO AND MYLAN GAVE TEVA PERMISSION TO SELL THE EPIPEN.
THERE IS NOTHING ELSE!!
TEVA SHOULD OWN THE MARKET INTO THE FUTURE!
Trade active:
ADDING 25,000 SHARES @ 23.85
Wall Street has no idea just how big the Teva Epipen Generic is.
The FDA is working with Mylan to extend the "OLD" Epipen expiration due to a HUGE SHORTAGE.
I would never trust an expired Epipen for food allergies with or without FDA Approval of the extension.
Wall Street has no idea just how big the Teva Epipen Generic is.
The FDA is working with Mylan to extend the "OLD" Epipen expiration due to a HUGE SHORTAGE.
I would never trust an expired Epipen for food allergies with or without FDA Approval of the extension.
Trade active:
ADDING 25,000 SHARES @ $23.15
THE OUTRAGEOUS MARKETWATCH ARTICLE THAT WAS JUST PUBLISHED "FOR THE SHORT SELLERS" IS WRONG.
TEVA IS AND WILL LAUNCH THE GENERIC EPIPEN VERY SHORTLY!
USE THE PULL BACK AS A BUYING OPPORTUNITY!
THE OUTRAGEOUS MARKETWATCH ARTICLE THAT WAS JUST PUBLISHED "FOR THE SHORT SELLERS" IS WRONG.
TEVA IS AND WILL LAUNCH THE GENERIC EPIPEN VERY SHORTLY!
USE THE PULL BACK AS A BUYING OPPORTUNITY!
Trade active:
News
BIG NEWS JUST HIT THE WIRES OR SHOULD I SAY SELECT WIRES...
Antares Pharma Inc., ATRS 0.83% which is manufacturing the injection device for Teva’s generic, said it has already shipped $22 million of product to Teva
BIG NEWS JUST HIT THE WIRES OR SHOULD I SAY SELECT WIRES...
Antares Pharma Inc., ATRS 0.83% which is manufacturing the injection device for Teva’s generic, said it has already shipped $22 million of product to Teva
Trade active:
ADDING 25,000 SHARES
Teva recently received $22 MILLION DOLLARS worth of injection devices from Antares Pharma. NEWS IS FORTHCOMING
"I AM GUESSING AT THE FOLLOWING NUMBERS" ...
$22 Million "might" equal approx. 500,000 Epipens if Teva paid between $25 and $50 per injector.
If Teva prices the Generic Epipen out at between $175 to $275 per pack of one (1) and two (2)... to beat Mylan's prices of $300/$600 per pack of two (2)...
Revenue should come in between $75 to $150 Million on the low side.
I will continue saying this to everyone as a comparison...
Tandem Diabetes TNDM sells diabetic pumps. Last qtr, they "only" sold around 6000 pumps because pumps do not need to be upgraded, it's not a must upgrade device. Tandem stock is upwards of $40 s share. The company to buy "is not" Tandem, it's the company that sells the insulin for people with diabetes.
Also, there are other Private and Public companies that sell Diabetic Pumps.
With TEVA, there is no one else besides Mylan that sells the Epipen and Mylan is a poorly run company as shown by all the manufacturing problems they are having.
The $1 BILLION DOLLAR Epipen Market is wide open for Teva to take.
Also, the Teva Generic Epipen "MUST" continue to be purchased by consumers with allergies as they expire therefore the price of TEVA's stock is sounding the DIRT CHEAP alarm.
It is my opinion that Teva SHOULD NOT BE TRADING LOWER than $50 a share just from the Generic Epipen potential.
LONG!
Teva recently received $22 MILLION DOLLARS worth of injection devices from Antares Pharma. NEWS IS FORTHCOMING
"I AM GUESSING AT THE FOLLOWING NUMBERS" ...
$22 Million "might" equal approx. 500,000 Epipens if Teva paid between $25 and $50 per injector.
If Teva prices the Generic Epipen out at between $175 to $275 per pack of one (1) and two (2)... to beat Mylan's prices of $300/$600 per pack of two (2)...
Revenue should come in between $75 to $150 Million on the low side.
I will continue saying this to everyone as a comparison...
Tandem Diabetes TNDM sells diabetic pumps. Last qtr, they "only" sold around 6000 pumps because pumps do not need to be upgraded, it's not a must upgrade device. Tandem stock is upwards of $40 s share. The company to buy "is not" Tandem, it's the company that sells the insulin for people with diabetes.
Also, there are other Private and Public companies that sell Diabetic Pumps.
With TEVA, there is no one else besides Mylan that sells the Epipen and Mylan is a poorly run company as shown by all the manufacturing problems they are having.
The $1 BILLION DOLLAR Epipen Market is wide open for Teva to take.
Also, the Teva Generic Epipen "MUST" continue to be purchased by consumers with allergies as they expire therefore the price of TEVA's stock is sounding the DIRT CHEAP alarm.
It is my opinion that Teva SHOULD NOT BE TRADING LOWER than $50 a share just from the Generic Epipen potential.
LONG!
Trade active:
ADDING 25,000 SHARES
PRICE: $22.55
THE PRICE OF TEVA'S STOCK IS A BARGAIN
BIG NEWS IS ON ITS WAY!
ADDING ON EVERY DIP
PRICE: $22.55
THE PRICE OF TEVA'S STOCK IS A BARGAIN
BIG NEWS IS ON ITS WAY!
ADDING ON EVERY DIP
Trade active:
YET HERE IS ANOTHER STOCK THAT WENT DOWN TODAY AND WHY?
B/C A BUNCH OF HOSPITALS ARE FORMING A NON-PROFIT COMPANY TO MAKE DRUGS?
YES, THIS WAS THE REASON.
WALL STREET DID NOT THINK ABOUT HOW LONG IT WILL TAKE THIS SO CALLED GROUP OF FINANCIALLY UNFIT HOSPITALS TO GET EACH DRUG APPROVED THAT WILL TAKE YEARS TO CREATE.
WALL STREET DID NOT THINK ABOUT ... BY THE TIME THESE FINANCIALLY UNFIT GROUP OF HOSPITALS PUT TOGETHER ONE DRUG, A NEWER DRUG OF THAT TYPE WILL BE FDA APPROVED BY ANOTHER DRUG COMPANY
THIS SO CALLED GROUP OF HOSPITALS ARE SO FAR BEHIND THE INDUSTRY, IT WILL TAKE THEM DECADES TO CATCH UP WITH BILLIONS IN WASTED CASH ALONG THE WAY!
SO I CONTINUE TO LOWER MY COST IN TEVA TOO!
B/C A BUNCH OF HOSPITALS ARE FORMING A NON-PROFIT COMPANY TO MAKE DRUGS?
YES, THIS WAS THE REASON.
WALL STREET DID NOT THINK ABOUT HOW LONG IT WILL TAKE THIS SO CALLED GROUP OF FINANCIALLY UNFIT HOSPITALS TO GET EACH DRUG APPROVED THAT WILL TAKE YEARS TO CREATE.
WALL STREET DID NOT THINK ABOUT ... BY THE TIME THESE FINANCIALLY UNFIT GROUP OF HOSPITALS PUT TOGETHER ONE DRUG, A NEWER DRUG OF THAT TYPE WILL BE FDA APPROVED BY ANOTHER DRUG COMPANY
THIS SO CALLED GROUP OF HOSPITALS ARE SO FAR BEHIND THE INDUSTRY, IT WILL TAKE THEM DECADES TO CATCH UP WITH BILLIONS IN WASTED CASH ALONG THE WAY!
SO I CONTINUE TO LOWER MY COST IN TEVA TOO!
Trade active:
TEVA should run up with the recent FDA Approval of the Migraine Drug that the company PURPOSELY announced after the close to RUIN THE SHORT SELLERS WEEKEND!
Trade active:
ADDED 50,000 SHARES TODAY
PRICE: $21.20
POSITIVE NEWS FORTHCOMING!
PRICE: $21.20
POSITIVE NEWS FORTHCOMING!